Literature DB >> 20880254

Factor XIII: novel structural and functional aspects.

I Komáromi1, Z Bagoly, L Muszbek.   

Abstract

Factor (F)XIII is a protransglutaminase that, in addition to maintaining hemostasis, has multiple plasmatic and intracellular functions. Its plasmatic form (pFXIII) is a tetramer of two potentially active A (FXIII-A) and two inhibitory/carrier B (FXIII-B) subunits, whereas its cellular form (cFXIII) is a dimer of FXIII-A. FXIII-A belongs to the family of transglutaminases (TGs), which show modest similarity in the primary structure, but a high degree of conservatism in their domain and sub-domain secondary structure. FXIII-A consists of an activation peptide, a β-sandwich, a catalytic and two β-barrel domains. FXIII-B is a glycoprotein consisting of 10 repetitive sushi domains each held together by two internal disulfide bonds. The structural elements of FXIII-A involved in the interaction with FXIII-B have not been elucidated; in FXIII-B the first sushi domain seems important for complex formation. In the circulation pFXIII is bound to the fibrinogen γ'-chain through its B subunit. In the process of pFXIII activation first thrombin cleaves off the activation peptide from FXIII-A, then in the presence of Ca(2+) FXIII-B dissociates and FXIII-A becomes transformed into an active transglutaminase (FXIIIa). The activation is highly accelerated by the presence of fibrin(ogen). cFXIII does not require proteolysis for intracellular activation. The three-dimensional structure of FXIIIa has not been resolved. Based on analogies with transglutaminase-2, a three-dimensional structure of FXIIIa was developed by molecular modeling, which shows good agreement with the drastic structural changes demonstrated by biochemical studies. The structural requirements for enzyme-substrate interaction and for transglutaminase activity are also reviewed.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20880254     DOI: 10.1111/j.1538-7836.2010.04070.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  47 in total

1.  A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.

Authors:  Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

2.  Reversible activation of cellular factor XIII by calcium.

Authors:  Gunhild Klarskov Kristiansen; Mette Dahl Andersen
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

3.  Free-radical oxidation of plasma fibrin-stabilizing factor.

Authors:  M A Rosenfeld; A N Shegolihin; A V Bychkova; V B Leonova; E A Kostanova; M I Biryukova; S D Razumovskii; M L Konstantinova
Journal:  Dokl Biochem Biophys       Date:  2012-11-07       Impact factor: 0.788

4.  Structural basis for biofilm formation via the Vibrio cholerae matrix protein RbmA.

Authors:  Krista M Giglio; Jiunn C Fong; Fitnat H Yildiz; Holger Sondermann
Journal:  J Bacteriol       Date:  2013-05-17       Impact factor: 3.490

5.  Activation of factor XIII is accompanied by a change in oligomerization state.

Authors:  Boris A Anokhin; Vilius Stribinskis; William L Dean; Muriel C Maurer
Journal:  FEBS J       Date:  2017-10-03       Impact factor: 5.542

Review 6.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

7.  Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion.

Authors:  Harini Raghu; Carolina Cruz; Cheryl L Rewerts; Malinda D Frederick; Sherry Thornton; Eric S Mullins; Jonathan G Schoenecker; Jay L Degen; Matthew J Flick
Journal:  Blood       Date:  2014-10-21       Impact factor: 22.113

8.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

Review 9.  The multifaceted role of fibrinogen in tissue injury and inflammation.

Authors:  James P Luyendyk; Jonathan G Schoenecker; Matthew J Flick
Journal:  Blood       Date:  2018-12-06       Impact factor: 22.113

10.  The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Authors:  Jan Astermark; Sharyne M Donfield; Edward D Gomperts; John Schwarz; Erika D Menius; Anna Pavlova; Johannes Oldenburg; Bailey Kessing; Donna M DiMichele; Amy D Shapiro; Cheryl A Winkler; Erik Berntorp
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.